Exon skipping oligomer conjugates for muscular dystrophy

Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described in Formula (I). The antisense oligomer conjugate has addition of an R6-G-peptide group with the terminal acetyl group at the 3' end.

Saved in:
Bibliographic Details
Main Authors Passini, Marco A, Hanson, Gunnar J
Format Patent
LanguageEnglish
Published 26.05.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described in Formula (I). The antisense oligomer conjugate has addition of an R6-G-peptide group with the terminal acetyl group at the 3' end.
Bibliography:Application Number: NZ20170755416